GLAXO WELLCOME VALTREX POSTS $7.8 MIL. IN SALES AFTER SEPTEMBER LAUNCH; ZANTAC SALES DOWN 4%; GLAXO PREDICTS FOUR PRODUCT LAUNCHES FOR THIS YEAR
Executive Summary
Glaxo Wellcome's Valtrex contributed $7.8 mil. (œ5 mil.) in U.S. sales in 1995 after its September launch. FDA approved Valtrex for shingles in June and for recurrent genital herpes in December. Worldwide sales of Valtrex (valacyclovir) were $14 mil., CEO Richard Sykes told a meeting of securities analysts in New York City March 7.